The Legacy and Potential of EOM613
EOM613 is the lead product candidate being developed by EOM Pharmaceuticals. It is an investigational, first-in-class, dual-acting, broad-spectrum immunomodulator designed to have both an anti-inflammatory effect specifically at the site of cytokine and chemokine overactivity, and a pro-inflammatory effect, when needed to restore physiological balance.
Distinct from conventional immunomodulators, which generally target a single process of the immune response either pro- or anti-inflammatory, EOM613 is designed to modulate the body’s fine balance of pro-inflammatory and anti-inflammatory cytokines and chemokines to counteract the most severe inflammatory effects of viruses, such as cytokine storm following infection with the novel coronavirus that causes COVID-19, autoimmune attacks that cause joint damage and pain associated with rheumatoid arthritis, and chemokine-related body-wasting syndromes such as cachexia.
By re-establishing normal physiological immune balance, EOM613 serves to rescue, repair, and restore an immune system that has been confronted by an invading antigen, pathogen, or virus. This dual-acting, broad-spectrum approach may overcome a key limitation of conventional immunomodulators. EOM613 has already demonstrated clinical improvements in various disease states and immune-related biomarkers and general tolerability across five Phase 2 clinical trials in patients with AIDS, cancer cachexia and rheumatoid arthritis. It is administered as a subcutaneous injection, unlike conventional immunomodulators which often require intravenous infusion. EOM613 is efficiently manufactured from readily available materials.